Literature DB >> 27267778

Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.

Ann Mary Joseph1, Ratika Srivastava2, Jovanny Zabaleta3, Eduardo Davila4.   

Abstract

The activation of TLR-MyD88 (Toll-like receptor-myeloid differentiation factor 88) signaling within T cells functions as a potent costimulatory signal that boosts antitumor and antiviral responses. However, the molecular mechanisms underlying the costimulatory processes are poorly understood. We compared microarray gene analysis data between TLR1-TLR2-stimulated and unstimulated T-cell receptor transgenic "pmel" and MyD88(-/-) pmel CD8(+) T cells and identified changes in the expression of several TNF family members. In particular, TLR stimulation increased 4-1BB levels in pmel but not in MyD88(-/-)pmel T cells. A link between 4-1BB and TLR1-TLR2 signaling in CD8(+) T cells was highlighted by the suboptimal responses of 4-1BB(-/-) T cells to TLR1-TLR2 agonist, but their normal response to CD28 or OX40 costimulation. Blocking 4-1BB signaling with antibodies also hindered the costimulatory effects of the TLR1-TLR2 agonist. The elevated levels of 4-1BB transcripts in TLR1-TLR2-stimulated cells were not due to increased mRNA stability nor increased histone activation, but instead were associated with increased binding of p65 and c-Jun to two distinct 4-1BB promoter sites. Combining TLR1-TLR2 ligand with an agonistic antibody to 4-1BB enhanced the antitumor activity in mice with established melanoma tumors. These studies reveal that the costimulatory effects of TLR1-TLR2 signaling in CD8(+) T cells are in part mediated by 4-1BB and are important for mounting an effective antitumor immune response. Cancer Immunol Res; 4(8); 708-16. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27267778      PMCID: PMC4970957          DOI: 10.1158/2326-6066.CIR-15-0173

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  34 in total

1.  The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells.

Authors:  Guoxing Zheng; Bin Wang; Aoshuang Chen
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

Review 2.  T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.

Authors:  Laura M Snell; Gloria H Y Lin; Ann J McPherson; Theo J Moraes; Tania H Watts
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

3.  Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant.

Authors:  Jung D Kim; Chang H Kim; Byoung S Kwon
Journal:  Mol Cells       Date:  2011-01-11       Impact factor: 5.034

4.  Unified immune modulation by 4-1BB triggering leads to diverse effects on disease progression in vivo.

Authors:  Beom K Choi; Young H Kim; Jae H Choi; Chang H Kim; Kwang-Soon Kim; Young-Chul Sung; Young-Min Lee; John R Moffett; Byoung S Kwon
Journal:  Cytokine       Date:  2011-06-22       Impact factor: 3.861

5.  Triggering of TNFRSF25 promotes CD8⁺ T-cell responses and anti-tumor immunity.

Authors:  Tomasz J Slebioda; Tania F Rowley; John R Ferdinand; Jane E Willoughby; Sarah L Buchan; Vadim Y Taraban; Aymen Al-Shamkhani
Journal:  Eur J Immunol       Date:  2011-08-04       Impact factor: 5.532

Review 6.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

Review 7.  Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.

Authors:  Chao Wang; Gloria H Y Lin; Ann J McPherson; Tania H Watts
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

8.  4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.

Authors:  Beom K Choi; Jun S Bae; Eun M Choi; Woo J Kang; Shimon Sakaguchi; Dass S Vinay; Byoung S Kwon
Journal:  J Leukoc Biol       Date:  2003-12-23       Impact factor: 4.962

Review 9.  IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.

Authors:  Mads Gyrd-Hansen; Pascal Meier
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

10.  CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.

Authors:  K Saoulli; S Y Lee; J L Cannons; W C Yeh; A Santana; M D Goldstein; N Bangia; M A DeBenedette; T W Mak; Y Choi; T H Watts
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

View more
  3 in total

1.  A Synthetic CD8α:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Jitao Guo; Alexander K Tsai; Jackline Joy Lasola; Kenisha Younger; Yuji Zhang; Cruz Velasco Gonzales; Eduardo Davila
Journal:  Cancer Res       Date:  2017-10-20       Impact factor: 12.701

Review 2.  Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana
Journal:  Drug Discov Today       Date:  2021-01-12       Impact factor: 8.369

Review 3.  Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases.

Authors:  Ejuan Zhang; Zhiyong Ma; Mengji Lu
Journal:  Cell Mol Life Sci       Date:  2022-10-12       Impact factor: 9.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.